EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Elevations in Donor-Derived Cell-Free DNA and Allograft Outcomes in Kidney Transplantation

Jeffrey A. Klein, David Taber, David Wojciechowski, Didier A. Mandelbrot, Renata Glehn-Ponsirenas, Oyedolamu Olaitan, Pranjal Jain, James Lu, Martina M. McGrath, Mohanram Narayanan, Anup M. Patel, Massini Merzkani, Nitipong Permpalung, Rashikh A. Choudhury, Michelle A. Josephson, Sanjiv Anand, Pradeep Vaitla, Eric Langewisch, Maria Ajaimy, Dhiren Kumar, George W. Burke, Todd E. Pesavento, Anthony J. Langone, Yihung Huang, David Leeser, Bernard Fischbach, Nadiesda Costa, Kalathil Sureshkumar, Abd A. Qannus, Chun-Po Steve Fan, Ziad Zaky, Fuad Shihab, Sanjay Kulkarni, Thin Thin Maw, Bekir Tanriover, Enver Akalin, Matthew Cooper, Ibrahim Tawhari, Matthew R. Weir, Tarek Alhamad

Journal of the American Society of Nephrology · 2026-11 · 37 (11) · 2517-2528

DOI: 10.1681/asn.0000001133 ↗
AbstractBibliografische Angaben

Abstract

Key Points We assessed whether an initial donor-derived cell-free DNA elevation during routine surveillance was associated with allograft dysfunction and loss in kidney transplant recipients. Intermediate and high donor-derived cell-free DNA states were independently associated with 3.7-fold and 6.4-fold higher risks of allograft loss, respectively. Persistently low donor-derived cell-free DNA levels were associated with low rates of rejection and allograft loss, identifying a low-risk population. Background Although donor-derived cell-free DNA (dd-cfDNA) correlates with histologic rejection and injury severity, its association with long-term graft outcomes has yet to be well established in kidney transplant recipients. We hypothesize that among patients monitored with dd-cfDNA, an initial elevation may be associated with subsequent allograft dysfunction and loss. Methods The Kidney Allograft Outcomes AlloSure Registry is a prospective, multicenter cohort of 1743 adult kidney transplant recipients from 56 US centers; this analysis included 1258 patients who initiated dd-cfDNA surveillance 15–60 days post-transplant with up to 3-year follow-up. A multistate model was applied to characterize transitions from a low dd-cfDNA state (no elevations) to intermediate (0.5%–1.0% with ≥61% relative change value) or high (≥1.0%) dd-cfDNA states, and their unadjusted and covariate-adjusted associations with allograft loss or all-cause death were quantified using hazard regression models. Results Within 3 years, 36% of patients transitioned to an elevated dd-cfDNA state (intermediate n =216; high n =233). Allograft dysfunction by 36 months occurred significantly more often in patients with dd-cfDNA elevations despite preserved allograft function at the time of elevation (eGFR ≥60 ml/min per 1.73 m 2 in 42% of intermediate and 33% of high), consistent with subclinical injury. Transitions from low to elevated dd-cfDNA states were strongly associated with subsequent allograft loss (adjusted hazard ratios, 3.70 [95% confidence interval [CI], 1.38 to 9.90] for intermediate; 6.36 [95% CI, 2.80 to 14.42] for high), while mortality did not differ by dd-cfDNA state. Conclusions Initial dd-cfDNA elevations exceeding established thresholds were independently associated with higher risks of allograft dysfunction and loss across both elevation categories, whereas patients who remained in the low dd-cfDNA state experienced favorable outcomes.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →